Vericel Corporation is dedicated to the development of advanced cell therapies for the treatment of patients with severe diseases and conditions. Vericel currently markets two advanced cell therapy products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is a third generation autologous chondrocyte implant for the treatment of cartilage defects in the knee. Epicel® (cultured epidermal autografts) is a permanent skin replacement for full thickness burns greater than or equal to 30% of total body surface area. At this time Vericel is seeking partners to commercialize MACI and Epicel outside of the United States. Vericel is also seeking to acquire, co-develop or in-license products which leverage either the company’s existing sports medicine and burn care commercial capabilities, or the company’s proven cell therapy development, manufacturing and commercialization capabilities.